Evaxion Biotech Earnings Call Highlights AI and Runway

Evaxion Biotech A/S Adr ((EVAX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Evaxion Biotech’s latest earnings call struck an upbeat tone, as management highlighted strong clinical data, rapid platform innovation and a much-improved balance sheet that extends the cash runway into the second half of 2027. Risks around ongoing losses, potential dilution and the early-stage status of several programs remain, but momentum in both oncology and infectious disease pipelines appears to outweigh current headwinds.

EVX‑01 Delivers Standout Phase II Results in Melanoma

EVX‑01 continued to anchor the investment story with compelling two‑year Phase II data in advanced melanoma, including a 75% objective response rate and 25% complete response rate, with 92% of responders still in response at the two‑year mark. The vaccine also showed an 81% per‑antigen immunogenicity hit rate, a level management argued exceeds comparable programs and underpins confidence ahead of further biomarker and three‑year updates.

MSD Option on EVX‑B3 Validates AI‑Driven Discovery

Merck’s decision to exercise its option on EVX‑B3 was framed as a landmark validation, as management described it as the first known in‑licensing of an infectious disease vaccine candidate discovered and validated by an AI immunology platform. The move signals tangible commercial interest in Evaxion’s technology stack and suggests that its AI‑driven engine can generate assets attractive to major pharmaceutical partners.

EVX‑04 Shows Strong Preclinical Promise in AML

In acute myeloid leukemia, EVX‑04’s preclinical data showed robust and specific T‑cell responses against 16 optimized endogenous retroviral fragments, with prevention of tumor growth in multiple models. Management aims to translate this into the clinic, planning to submit a first‑in‑human clinical trial application in the second half of 2026, positioning EVX‑04 as a potential new immunotherapy option in a difficult blood cancer.

EVX‑B2 Gonorrhea Candidate Retains Full Upside

The company highlighted a comprehensive preclinical package for EVX‑B2, including significant protection in mouse infection models, broad activity across around 50 clinically relevant gonorrhea strains and potent complement‑mediated killing. These data, combined with both humoral and cellular responses, support EVX‑B2 as a differentiated asset in a high‑need area where Evaxion now holds full global rights.

CMV Program Leverages Multi‑Antigen and Engineering Strategy

Evaxion’s CMV candidate, EVX‑B1, employs a multi‑antigen approach that combines known glycoproteins with novel antigens, supported by AI‑guided engineering. A prefusion‑locked glycoprotein B construct designed by the platform showed superior neutralization versus the native form, and management believes this multicomponent design may help reduce viral escape risk over time.

Automated Design Module Accelerates Vaccine Development

Management underscored a key platform upgrade with the launch of an automated vaccine design module in October 2025, integrating multiomic data to produce ranked antigen lists within 24 hours. By improving construct expression, formulation and manufacturability, this tool is expected to cut both cost and time from discovery to design, strengthening Evaxion’s end‑to‑end development workflow.

Partnerships and Awards Boost External Validation

Beyond Merck, Evaxion pointed to a new collaboration with the Gates Foundation around polio vaccine design as evidence of its rising profile in global health. Recognition from the Galien Foundation for advances in AI for human health added further external validation, which management hopes will support broader partnering discussions across its pipeline.

Strengthened Balance Sheet and Extended Runway

Financially, Evaxion reported about $32 million of cash inflows in 2025 from financings, at‑the‑market activity and Merck’s option fee, as well as a debt‑to‑equity conversion with the European Investment Bank. The year ended with roughly $23 million in cash, an improved net loss of about $7.7 million and a runway now expected to reach into the second half of 2027, while warrant exercises trimmed potential dilution by around 1 million ADS equivalents.

MSD Passes on EVX‑B2, Shifting Development Burden

While the EVX‑B3 option was exercised, Merck chose not to take up its option on EVX‑B2, leaving Evaxion with both the full upside and full funding responsibility for the gonorrhea program. Management acknowledged that without a new partner, advancing EVX‑B2 into the clinic may be slower or more capital‑intensive, making future partnering or selective internal funding decisions a key watchpoint.

Partner Caution and Need for More Validation

Executives admitted that several potential partners remain hesitant, waiting for additional translational and clinical proof before committing to larger, definitive deals. They noted a historical challenge in turning technical strength into sizeable transactions, and see upcoming datasets as critical catalysts to convert current interest into concrete collaborations.

Persisting Losses, Dilution Risk and Financial Volatility

Despite progress, Evaxion remains unprofitable, with a net loss of about $7.7 million for 2025 as R&D and platform investments continue. Investors also face ongoing dilution risk from roughly 8.3 million ADS equivalents on an as‑converted basis and around 2.8 million remaining warrant equivalents, while derivative remeasurement and currency swings drove notable volatility in reported financials.

Operational Frictions and Early‑Stage Pipeline Risks

Management pointed to operational frictions, including a 24‑hour delay in the earnings call for technical reasons, as indicative of the non‑linear nature of both internal and partnered R&D. Many programs, including EVX‑04, several infectious disease vaccines and early autoimmune efforts, remain in preclinical or early translational stages, meaning that substantial value realization is still contingent on future clinical progress.

Guidance: Key 2026 Data Catalysts on the Horizon

Looking ahead, Evaxion guided to several 2026 milestones, including additional EVX‑01 biomarker and immunogenicity data in the first half and three‑year clinical results in the second half, alongside EVX‑B4 group B strep data later in the year. The company also plans to file a clinical application for EVX‑04 by the end of 2026 and provide more detail on its autoimmune initiatives, all while operating under a cash runway expected to last into the second half of 2027.

The call painted a picture of a company transitioning from pure discovery to clinically validated execution, led by standout EVX‑01 data and a strengthening infectious disease suite. For investors comfortable with early‑stage biotech risk, Evaxion’s AI‑enabled platform, growing external validation and improved runway offer meaningful upside potential, albeit with ongoing dilution, profitability and partnering risks to monitor closely.